Attempts at a peptide vaccine against paracoccidioidomycosis, adjuvant to chemotherapy.
Chemotherapy is the basis of treatment of paracoccidioidomycosis in its various forms. Depending on the Paracoccidioides brasiliensis virulence, the status of host immunity, the degree of tissue involvement and fungal dissemination, treatment can be extended for long periods with an alarming frequency of relapses. Association of chemotherapy with a vaccine to boost the cellular immune response seemed a relevant project not only to reduce the time of treatment but also to prevent relapses and improve the prognosis of anergic cases. The candidate immunogen is the gp43 major diagnostic antigen of P. brasiliensis and more specifically its derived peptide P10, carrying the CD4+ T-cell epitope. Both gp43 and P10 protected Balb/c mice against intratracheal infections with virulent P. brasiliensis strain. P10 as single peptide or in a multiple-antigen-peptide (MAP) tetravalent construction was protective without adjuvant either by preimmunization and intratracheal challenge or as a therapeutic agent in mice with installed infection. P10 showed additive protective effects in drug-treated mice stimulating a Th-1 type immune response with high IFN-gamma and IL-12. P10 and few other peptides in the gp43 were selected by Tepitope algorithm and actually shown to promiscuously bind several prominent HLA-DR molecules suggesting that a peptide vaccine could be devised for a genetically heterogenous population. P10 was protective in animals turned anergic, was effective in a DNA minigene vaccine, and increased the protection by monoclonal antibodies in Balb/c mice. DNA vaccines and peptide vaccines are promising therapeutic tools to be explored in the control of systemic mycoses.
Travassos
Luiz R
LR
Department of Microbiology, Immunology and Parasitology, Experimental Oncology Unit, Federal University of São Paulo, Rua Botucatu 862, 8 andar, São Paulo, SP 04023-062, Brazil. travassos@unifesp.br
Rodrigues
Elaine G
EG
Iwai
Leo K
LK
Taborda
Carlos P
CP
D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000595:Amino Acid Sequence; D000818:Animals; D000935:Antifungal Agents / Q000627:therapeutic use*; D000946:Antigens, Fungal / Q000737:chemistry / Q000276:immunology*; D003131:Combined Modality Therapy; D005656:Fungal Proteins / Q000737:chemistry / Q000276:immunology*; D005657:Fungal Vaccines / Q000008:administration & dosage / Q000138:chemical synthesis / Q000737:chemistry / Q000276:immunology; D006023:Glycoproteins / Q000737:chemistry / Q000276:immunology*; D006801:Humans; D051379:Mice; D008807:Mice, Inbred BALB C; D008969:Molecular Sequence Data; D010228:Paracoccidioides / Q000276:immunology*; D010229:Paracoccidioidomycosis / Q000382:microbiology / Q000517:prevention & control*; D010455:Peptides / Q000008:administration & dosage / Q000138:chemical synthesis / Q000737:chemistry / Q000276:immunology; D016896:Treatment Outcome; D014611:Vaccination
C103180:43 kDa protein, Paracoccidioides; D000276:Adjuvants, Immunologic; D000935:Antifungal Agents; D000946:Antigens, Fungal; D005656:Fungal Proteins; D005657:Fungal Vaccines; D006023:Glycoproteins; D010455:Peptides
Infect Immun. 2003 Sep;71(9):5273-9
12933874
Mol Med. 2003 Sep-Dec;9(9-12):209-19
15208742
Curr Mol Med. 2005 Jun;5(4):393-401
15977995
Blood. 2004 Apr 1;103(7):2668-76
14630812
Arch Biochem Biophys. 1991 Sep;289(2):298-302
1898073
Trends Mol Med. 2006 Jan;12(1):6-9
16309965
Peptides. 2002 Oct;23(10):1727-33
12383859
J Antimicrob Chemother. 2004 Nov;54(5):956-8
15448128
Am J Trop Med Hyg. 1990 Aug;43(2):200-6
2389824
Infect Immun. 2003 Nov;71(11):6534-42
14573675
Infect Immun. 2007 Jul;75(7):3680-2
17452471
J Med Vet Mycol. 1994;32(1):77-81
7515959
Cell Immunol. 1998 Nov 25;190(1):68-76
9826448
J Immunol. 2001 Jan 15;166(2):1087-96
11145689
Antimicrob Agents Chemother. 2006 Aug;50(8):2814-9
16870776
J Immunol. 2005 May 15;174(10):6282-91
15879127
Vaccine. 2000 Jul 1;18(26):3050-8
10825609
Infect Immun. 2000 Dec;68(12):7172-4
11083850
Microbes Infect. 2007 Mar;9(3):308-16
17306589
J Clin Invest. 2000 Dec;106(11):1381-9
11104791
Vaccine. 2005 Jun 10;23(30):3961-72
15917118
Infect Immun. 1986 Jul;53(1):199-206
2424841
Cell Microbiol. 2004 Oct;6(10):953-61
15339270
Nat Rev Microbiol. 2007 Jan;5(1):13-28
17160002
Hum Mol Genet. 1992 Sep;1(6):363-9
1301910
J Clin Invest. 2005 Dec;115(12):3536-44
16308571
Scand J Immunol. 2004 Jan;59(1):58-65
14723622
Clin Vaccine Immunol. 2007 Apr;14(4):474-6
17329443
Biotechnology. 1992;20:451-65
1600388
Infect Immun. 2003 Nov;71(11):6205-12
14573638
Infect Immun. 1998 Dec;66(12):6027-9
9826391
Scand J Immunol. 2003 Sep;58(3):290-7
12950674
Infect Immun. 1998 Feb;66(2):786-93
9453642
Microbes Infect. 2007 May;9(6):704-13
17412629
Infect Immun. 1997 Aug;65(8):3399-405
9234804
J Clin Microbiol. 2004 Oct;42(10):4480-6
15472297
Glycobiology. 2001 Aug;11(8):693-701
11479280
Nat Rev Drug Discov. 2007 May;6(5):404-14
17473845
J Immunol. 2007 Feb 15;178(4):2000-7
17277103
Infect Immun. 2006 May;74(5):3042-5
16622248
Infect Immun. 2005 Apr;73(4):2129-34
15784555
J Clin Microbiol. 2004 Jun;42(6):2419-24
15184413
Immunol Today. 1997 Apr;18(4):164-9
9136452
J Exp Med. 2005 Sep 5;202(5):597-606
16147975
Infect Immun. 2000 Mar;68(3):1649-54
10678984
Infect Immun. 1999 Feb;67(2):630-5
9916069